ImmPrev Bio Overview
- Year Founded
-
2022
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
ImmPrev Bio General Information
Description
Developer of a novel diagnostic tool designed to support early-stage intervention for Crohn's disease. The company offers a concomitant metabolic checkpoint inhibition therapy for inflammatory bowel disease backed by strong preclinical proof-of-concept data, enabling healthcare providers to identify and deliver targeted treatment solutions for patients with inflammatory bowel conditions.
Contact Information
Corporate Office
- Birmingham, AL
- United States
Corporate Office
- Birmingham, AL
- United States
ImmPrev Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 02-Aug-2023 | Completed | Startup |
ImmPrev Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ImmPrev Bio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| First Avenue Ventures | Accelerator/Incubator | Minority |
ImmPrev Bio FAQs
-
When was ImmPrev Bio founded?
ImmPrev Bio was founded in 2022.
-
Where is ImmPrev Bio headquartered?
ImmPrev Bio is headquartered in Birmingham, AL.
-
What industry is ImmPrev Bio in?
ImmPrev Bio’s primary industry is Drug Discovery.
-
Is ImmPrev Bio a private or public company?
ImmPrev Bio is a Private company.
-
What is ImmPrev Bio’s current revenue?
The current revenue for ImmPrev Bio is .
-
Who are ImmPrev Bio’s investors?
First Avenue Ventures has invested in ImmPrev Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
